Taçoy, Gülten Gazi Üniversitesi - School of Medicine - Department of Cardiology, Turkey , Okyay, Kaan Gazi Üniversitesi - School of Medicine - Department of Cardiology, Turkey , Boyacı, Bülent Gazi Üniversitesi - School of Medicine - Department of Cardiology, Turkey

PULMONER ARTERİYEL HİPERTANSİYON HASTALARININ TEDAVİSİNDE VAZOAKTİF AJANLARIN ETKİNLİĞİ

17340

Pulmonary arterial hypertension (PAH) is a rare vascular disease and associated with progressive increases of in pulmonary vascular resistance and pulmonary arterial pressure thatwhich leads to right ventricular failure and death. Idiopathic PAH, connective tissue disease, and congenital heart disease with left to right shunts cause PAH. The diagnosis of PAH is established hemodynamically with a mean pulmonary artery pressure 25 mmHg at rest and 30 mmhg mmHg in exercise. PAH must be taken into consideration for in patients which with complaints of progressive dyspnea although they have no underlying pulmonary or heart disease. TransthorasicTransthoracic echocardiography and right heart catheterization are important tools for diagnosis. The treatment as current approaches for treatment are prostanoid analogues, endothelin antagonists, and PDE-inhibitors. In our report we aimed to evaluate the effect of vasoactive agents in the treatment of patients with PAH.

111

Pulmonary Arterial Hypertension , Treatment , Sidenafil , Bosentan , Iloprost

Fırat Medical Journal

115